Table 6.
Comparison of treatment outcome of active and subclinical tuberculosis diseases among all 420 enrolled participants
| Active TB disease (n = 339) | Subclinical TB disease (n = 81) | p value | |
|---|---|---|---|
| Mortalitya | |||
| Number (%) | 26 (8.3%) | 1 (1.2%) | 0.025d |
| OR (95% CI) | Reference | 0.14 (0.02–1.04) | 0.054 |
| Adjusted ORc (95% CI) | Reference | 0.20 (0.03–1.55) | 0.123 |
| Treatment successb | |||
| Number (%) | 278 (82.0%) | 71 (87.7%) | 0.223d |
| OR (95% CI) | Reference | 0.64 (0.31–1.32) | 0.226 |
| Adjusted ORc (95% CI) | Reference | 0.74 (0.36–1.53) | 0.412 |
TB tuberculosis, OR odds ratio, CI confidence interval
aIncidence of mortality during or before anti-TB treatment
bSum of cured and treatment completed cases; For tuberculosis susceptible to both isoniazid and rifampicin, treatment success was determined within 1 year of anti-TB treatment. For tuberculosis resistant to either isoniazid or rifampicin, treatment success was determined during the treatment period regardless of duration
cAdjusted by age and gender
dChi-square test